{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', '10.5', 'Cohorts for Analysis', '10.5.1 Total Vaccinated cohort - ZOSTER-006 and ZOSTER-022', 'The primary analysis of EQ-5D and SF-36 questionnaires will be performed on the TVC.', 'The TVC will include all subjects analysed from centres that participated in ZOSTER-', '064 and all subjects who had a HZ suspected event in either the ZOSTER-006 or', 'ZOSTER-022 studies.', '10.5.2 Modified Total Vaccinated Cohort', 'The mTVC will be the population-include only subjects from centres that participate in', 'ZOSTER-064 (i.e. these subjects that were included in the mTVC of ZOSTER-006 and', 'ZOSTER-022), which will exclude subjects in the TVC who were not administered the', 'second vaccination or who developed a confirmed case of HZ prior to 1 month after the', 'second vaccination.', '10.7.4 Definition of Frailty', 'Table 3 Detail of frailty components', 'Item', 'Scoring method based on response', 'Max Contribution to', 'to question', 'Frailty Index', 'Medical history', 'Cancer', '1', 'Diabetes Mellitus', '1', 'High Blood Pressure', '1', 'Myocardial Infarction Heart Attack', '1', 'CHF', '1', 'Cerebrovascular Disease', '1', 'Arthritis', '1', 'Chronic Lung Disease', '1', 'Stomach or Intestinal disorders Ulcers', '1', 'Migraine', '1', 'Cataract', '1', 'Glaucoma', '1', 'Total', '41', 'If the frailty index is less than or equal to 0.08 then the subject is classified as Non-Frail.', 'If the score is greater than 0.08 but less than or equal to 0.25 then the subject is classified', 'as pre-frail. If the score is greater than or equal to 0.25 then the subject is classified as', 'Frail.', '10.7.7.2 Cell Mediated Response', 'If data allows, CMI response will only be assessed and analysed in the CMI component', 'of the Immunogenicity subset for subjects in the ZOSTER-006 study.', '11-FEB-2019', '77', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', '12. COUNTRY SPECIFIC REQUIREMENTS', '12.1 Requirements for Japan', '12.1.1 Regulatory and Ethical Considerations', 'The study will be conducted in accordance with \"the Ministerial Ordinance on the', 'Standards for the Conduct of Clinical Trials of Medicinal Products (Ministry of Health', 'and Welfare [MHW] No.28 dated 27th March 1997)\" and, Law for Ensuring the Quality,', 'Efficacy, and Safety of Drugs and Medical Devices.', 'The statement \"I acknowledge that I am responsible for the overall study conduct.\" on the', \"Investigator Protocol Agreement Page means the investigator's responsibility as defined\", 'by Japanese GCP.', 'Study Monitoring', 'Direct access to essential documents by monitors, the scope of those documents, and', 'collection of information on safety according to the Japanese local regulation for the', 'post-marketing clinical study will be specified separately in the written procedures for', 'monitoring prepared for this study.', '12.1.2', 'Study period', 'Study period is included in the Exhibit.', '12.1.3 Study administrative structure', 'Sponsor information and List of Medical Institutions and Investigators are included in', 'the Exhibit.', '11-FEB-2019', '78', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'GlaxoSmithKline Biologicals SA', 'Vaccines R &D', 'Protocol Administrative Change 2', 'eTrack study number', '204878 (ZOSTER-064)', 'and Abbreviated Title', 'IND number', 'BB-IND-13857', 'Administrative change', 'Administrative change 2', 'number:', 'Administrative change', '13 November 2018', 'date:', 'PPD', 'Co-ordinating author:', 'Lead Scientific Writer', ',', 'Rationale/background for changes:', 'Typographical errors corrected', 'Amended text has been included in bold italics and deleted text in strikethrough in', 'the following sections:', 'Synopsis', 'Enppoints', 'Secondary', 'SF-36 and EQ-5D scale scores:', '- At months 0, 14, 26 and 38.', 'Confirmed HZ cases:', '-', 'Incidence of HZ cases during ZOSTER-006 and ZOSTER-022 for subjects in', 'the modified Total Vaccinated Cohort (mTVC).', 'Humoral Immunogenicity of the study vaccine in subset of subjects from', 'ZOSTER-006 and ZOSTER-022.', '-', 'Anti-gE Ab and anti-VZV Ab concentrations as determined by Enzyme-linked', 'Immunosorbent Assay (ELISA), in a subset of subjects at Months 0, 3, 14, 26', 'and 38.', '11-FEB-2019', '79', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}